In the process of glycolytic reprograming, TPI1, one of the key enzymes, have been shown to be closely associated with the deterioration of many cancers, such as intrahepatic cholangiocarcinoma [31, 32], pancreatic cancer [33], breast cancer [34], and lung cancer [35, 36]. This evidence concerns the gene TPI1 and lung carcinoma.